| 2023 | United States | Filed / under investigation | In November 2023, GSK filed a lawsuit against Moderna Inc. in U.S. federal court in Delaware, accusing the company of violating GSK's patents related to messenger RNA (mRNA) technology. The lawsuit cl Wikipedia: GSK plc（Controversies） | — |
| 2022-05-02 | United States | Judgment against company | Swiss Scientist Convicted by Federal Jury of Conspiracy to Steal Trade Secrets Belonging to GlaxoSmithKline U.S. Department of Justice + 1 more reports | — |
| 2022-01-03 | United States | Guilty plea / conviction | Fourth Defendant Pleads Guilty to Stealing Trade Secrets from GlaxoSmithKline to Benefit Chinese Pharma Company U.S. Department of Justice | — |
| 2021-08-05 | United States | Filed / under investigation | Glaxosmithkline LLC v. Teva Pharmaceuticals USA, Inc. Court of Appeals for the Federal Circuit | — |
| 2020-10-02 | United States | Filed / under investigation | Glaxosmithkline LLC v. Teva Pharmaceuticals USA, Inc. Court of Appeals for the Federal Circuit | — |
| 2018-09-26 | United States | Other | Peter Humphrey v. GlaxoSmithKline PLC Court of Appeals for the Third Circuit | — |
| 2018-08-22 | United States | Filed / under investigation | Wendy B. Dolin v. GlaxoSmithKline LLC Court of Appeals for the Seventh Circuit + 2 more reports | $3 million |
| 2018-03-30 | United States | Filed / under investigation | Trisvan v. Heyman District Court, E.D. New York | — |
| 2018-03-08 | United States | Judgment for company / dismissed | GlaxoSmithKline LLC v. Teva Pharm. USA, Inc. District Court, D. Delaware | — |
| 2017-08-04 | United States | Judgment for company / dismissed | Akerman v. GlaxoSmithKline, LCC District Court, D. Massachusetts | — |
| 2017-06-02 | United States | Other | Stephen Wendell v. Glaxosmithkline LLC Court of Appeals for the Ninth Circuit | — |
| 2016-02-17 | United States | Other | United States Ex Rel. Hamrick v. Glaxosmithkline LLC Court of Appeals for the First Circuit | — |
| 2016 | United Kingdom | Fine / administrative sanction | In February 2016, the company was fined over £37 million in the UK by the Competition and Markets Authority for paying Generics UK, Alpharma and Norton Healthcare more than £50m between 2001, and 2004 Wikipedia: GSK plc（Controversies） | £37 million |
| 2015-03-06 | United States | Filed / under investigation | United States ex rel. Thorpe v. GlaxoSmithKline PLC District Court, D. Massachusetts | — |
| 2014 | United Kingdom | Filed / under investigation | The UK's Serious Fraud Office (SFO) opened a criminal inquiry in 2014 into GSK's sales practices, using powers granted by the Bribery Act 2010 . The SFO said it was collaborating with Chinese authorit Wikipedia: GSK plc（Controversies） | — |
| 2013-11-01 | United States | Settlement | Off-Label Drug Promotion and the Use of Disclaimers* Texas law review | $3 billion |
| 2013 | China | Fine / administrative sanction | In 2013, Chinese authorities announced that, since 2007, GSK had funnelled HK$3.8 billion in kickbacks to GSK managers, doctors, hospitals and others who prescribed their drugs, using over 700 travel Wikipedia: GSK plc（Controversies） + 1 more reports | US$490 million |
| 2013 | China | Filed / under investigation | Philips T (26 July 2013). "Chinese police allege Glaxo sales reps trained to offer sexual bribes" . The Daily Telegraph . Archived from the original on 11 January 2022. Wikipedia: GSK plc（Controversies） + 1 more reports | — |
| 2013 | United States | Settlement | As part of the settlement GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services , which obliged the company to make major changes in the way it did busi Wikipedia: GSK plc（2012 criminal and civil settlement） | — |
| 2012 | United States | Settlement | 2012 | GlaxoSmithKline | $3 billion ($1B criminal, $2B civil) | Criminal: Off-label promotion, failure to disclose safety data. Civil: paying kickbacks to physicians, making false and misleading state Wikipedia: List of largest pharmaceutical settlements + 8 more reports | $3 billion / US$956,814,400 / US$43,185,600 |
| 2012 | United States | Settlement | The 2012 settlement included a criminal fine of US$242,612,800 for failing to report safety data to the FDA about Avandia ( rosiglitazone ), a diabetes drug approved in 1999, and a civil settlement of Wikipedia: GSK plc（Controversies） + 1 more reports | US$242,612,800 / US$657 million |
| 2010 | United States | Settlement | 2010 | GlaxoSmithKline | $750 million | Poor manufacturing practices | Kytril , Bactroban , Paxil CR , Avandamet | False Claims Act, FDCA Wikipedia: List of largest pharmaceutical settlements + 7 more reports | $750 million / US$150 million / US$600 million |
| 2008-09-19 | United States | Other | Johnson v. GlaxoSmithKline, Inc. California Court of Appeal | — |
| 2008-03-26 | United States | Other | Masters v. Glaxosmithkline Court of Appeals for the Second Circuit | — |
| 2006 | United States | Settlement | In 2006, in the United States GSK settled the largest tax dispute in IRS history, agreeing to pay US$3.1 billion. At issue were Zantac and other products sold in 1989 to 2005. The case revolved around Wikipedia: GSK plc（Controversies） | US$3.1 billion |
| 2005-07-14 | United States | Other | In Re GlaxoSmithKline Plc Supreme Court of Minnesota | — |
| 2004 | European Union | Judgment for company / dismissed | Italian police sought bribery charges in May 2004, against 4,400 doctors and 273 GSK employees. GSK and its predecessor were accused of having spent £152m on physicians, pharmacists and others, giving Wikipedia: GSK plc（Controversies） | — |
| 2003-11-24 | United States | Other | Pharmacia Corp. v. GlaxoSmithKline Consumer Healthcare, L.P. District Court, D. New Jersey + 1 more reports | — |
| 2003 | United States | Fine / administrative sanction | GSK was fined for promoting Paxil/Seroxat ( paroxetine ) for treating depression in the under-18s, although the drug had not been approved for pediatric use. Paxil had US$4.97 billion worldwide sales Wikipedia: GSK plc（Controversies） + 1 more reports | — |
| 2002 | United States | Settlement | The case began in 2002, when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorised; she was fired in 2003, and f Wikipedia: GSK plc（Controversies） | — |
| 2001 | United Kingdom | Fine / administrative sanction | In 2001, the British Advertising Standards Authority (ASA) required GSK to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay. A company poster showed bottl Wikipedia: GSK plc（Controversies） | US$217,000 |
| 2001 | United States | Filed / under investigation | For 10 years GSK marketed Paxil as non-habit forming. In 2001, 35 patients filed a class-action suit alleging they had had withdrawal symptoms, and in 2002, a Los Angeles court issued an injunction pr Wikipedia: GSK plc（Controversies） + 1 more reports | — |
| 1998 | United States | Other | The charges stemmed from GSK's promotion of the anti-depressants Paxil ( paroxetine ) and Wellbutrin ( bupropion ) for unapproved uses from 1998 to 2003, specifically as suitable for patients under th Wikipedia: GSK plc（Controversies） + 1 more reports | — |